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ABSTRACT
Our aim was to analyze the impact of a concurrent autoimmune disease on 
outcome of patients with early breast cancer. We reviewed medical charts of patients 
with a diagnosis of autoimmune diseases (AD) among a population of 17.153 cases. 
We categorized ADs as endocrine, rheumatic, systemic, neurological diseases and 
vasculitis. For each patient in the study group, we matched 2 patients. The events 
to determine overall survival (OS) and disease free survival (DFS) were identified 
from follow-up data. We identified 279 (1.62%) patients with early breast cancer 
and concurrent ADs. The median follow-up was 7.0 years. The 10-year OS rate was 
86% (95% CI, 80% to 91%) in the study group and 90% (95% CI, 86% to 93%) for 
the control group (p = 0.011). In patients with ER positive/HER2 negative subtype 
a worse OS was observed in the study group when compared to the control group 
(p = 0.0046); this difference remained statistically significant when the analysis 
was restricted to breast cancer mortality (p = 0.045). The 10-year DFS rate was 
69% (95% CI, 61% to 76%) in the study group and 72% (95% CI, 66% to 77%) 
for the control group (p = 0.22). Autoimmunity at diagnosis of early breast cancer is 
associated with worse survival.
INTRODUCTION 
Autoimmune diseases (ADs) affect approximately 
7–10% of individuals living in the western countries, 
representing a significant cause of morbidity, chronic 
disability and health-care burden [1]. A population-based 
cohort study of more than 20 000 1-year survivors of 
childhood cancer showed a significant, 1.4-fold increase 
in risk for a hospital contact for an autoimmune disease 
over that of the background population [2]. One hypothesis 
to explain the increase in risk for several autoimmune 
diseases is that persistent immune abnormalities after 
treatment with chemotherapy and the cancer itself 
predispose to the development of autoantibodies, which are 
central to the pathogenesis of many autoimmune diseases. 
On the other hand limited evidences are available on the 
outcome of patients affected by ADs who develop cancer. 
ADs are associated with activation of auto-reactive T and 
B lymphocytes, down-regulation of T regulators cell and 
release of pro-inflammatory cytokines leading to B and T 
cells tolerance loss. Natural and inducible CD4+ CD25+ 
Forkhead box P3 (FOXP3)+ regulatory T cells (Tregs) 
play a key role in maintaining immune self-tolerance, as 
they inhibit the activation and expansion of autoreactive 
immune clones; hence, their absence or functional defects 
favor the development of various autoimmune diseases 
[3]. Moreover Tregs are involved in the inhibition of 
effector functions in both inflammation and cancer; it has 
been shown that the presence of CD4+CD25+FOXP3+ 
regulatory T cells in cancer tissues is associated with 
mechanisms of tumor immune escape and worse prognosis 
[4, 5]. The expression of the transcription regulator FOXP3 
is necessary for Tregs suppressor function [6]. Also, loss 
or downregulation of FOXP3 lead to the acquisition of 
effector T cell properties [7]. T helper 17 cells (Th17), 
producing IL-17A, IL-17F, IL-21, IL-22 and IL- 26, are 
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important co-regulators. The balance between T reg and 
Th17 cells regulates TH1/TH2 shift in ADs [8]. However, 
little is known on the balance between Treg and Th17 cells 
in patients with cancer and on the active role played by 
Th 17 in anti-tumor immunity [9]. IL17 promotes host 
defenses against bacterial infection [10] and elevated levels 
of these cytokines have been associated to inflammatory 
systemic diseases such as rheumatoid arthritis (RA) and 
systemic lupus erythematosus (SEL) [11]. The presence 
of IL 17 in tumor tissues seems to be protective, due to its 
ability to activate CD8+ cell priming; however, its role is 
still controversial [12, 13]. Other important guardians of 
immune self-tolerance are dendritic cells (DC), which are 
involved in either initiating (mature DC) or silencing T cell 
responses (immature DCs- iDCs) [14]. The correlation 
between some ADs such as Sjogren syndrome, RA, SEL 
and lymphoproliferative malignancies is well established 
[15], as well as the association between dermatomyositis 
and the development of solid tumors [16]. Several studies 
have suggested that ADs may differently influence the 
risk of breast cancer (BC), either increasing it or reducing 
it. A recent review of the literature has highlighted the 
positive epidemiologic correlation between ulcerative 
colitis, psoriasis, Graves disease, multiple sclerosis and 
the development of BC [17–20]. Moreover, some therapies 
used in autoimmune diseases, such as tumor necrosis factor 
(TNF) blockers, eventually interact with the development 
of tumors, even though clinical studies on this topic 
showed discordant results. It is worth mentioning here that 
new immunomodulatory antibodies targeting Cytotoxic 
T-Lymphocyte Antigen 4 (CTLA-4) and Programmed 
Death-1 (PD-1), currently under investigation for cancer 
treatment, have important immune system related adverse 
events [21, 22]. The aim of our study was to investigate 
whether clinical features and tumor characteristics differ 
in BC patients with and without concurrent autoimmune 
comorbidities. We also assessed whether a concurrent 
ADs impact on BC outcome in terms of both disease free 
survival (DFS) and overall survival (OS).
RESULTS
We identified 279 (1,6%) patients with early 
breast cancer and concurrent ADs out of 17.153 cases 
screened (Table 1). We classified 149 (53.4%) patients 
with autoimmune endocrine diseases (i.e. thyroiditis, 
Basedow disease, type I diabetes),  66 (23.7%) with 
rheumatic diseases, 43 (15.4%) with systemic autoimmune 
diseases (i.e. SEL, scleroderma disease, Sjogren 
syndrome, sclerotic cholangitis), 14 (5%) with neurologic 
autoimmune like diseases (i.e. miastenia gravis, sclerosis 
multiple, Guillain-Barré syndrome) and 7 (2.5%) with 
vasculitis. Almost all patients included in the study group 
received an adjuvant therapy: 147 (52.7%) an endocrine 
therapy alone, 39 (14%) a chemotherapy alone and 72 
(25.2%) received chemotherapy and endocrine therapy; 
21 (7.5%) of patients received no treatment. Almost all 
patients included in the study group had an estrogen 
receptor (ER) positive/HER2 negative breast cancer 
(67.8%), 27 (9.7%) patients had a ER positive/ HER2 
positive breast cancer, 14 (5%) had an HER2 positive/
ER and PgR negative and 26 (8.2%) had a triple negative 
breast cancer. There was no significant correlation between 
age, menopausal status, histology, surrogate intrinsic 
subtypes and incidence of autoimmune disease. Baseline 
demographic, clinical, and pathologic characteristics and 
local and systemic treatments of breast cancer patients 
with autoimmune disease (AD) and a matched cohort of 
breast cancer patients without AD are reported in Table 1. 
The median follow-up was 7.0 years. We recorded the 
incidence of events in the study and control group. In the 
DFS analysis we observed 66 (23.7%) events in the ADs 
group and 117 (21%) in the control group. We recorded 25 
(9.0%) locoregional events and 22 (7.9%) distant events 
in the ADs group and 38 (6.8 %) locoregional events and 
42 (7.5%) distant events in the control group. The 5-year 
DFS rate was 80% (95% CI, 75% to 85%) in the study 
group and 86% (95% CI, 82% to 88%) for the control 
group. The 10-year DFS rate was 69% (95% CI, 61% 
to 76%) in the study group and 72% (95% CI, 66% to 
77%) for the control group (p = 0.22). In the OS analysis 
we observed 32 (11.5%) deaths in the ADs group and 
36 (6.4%) in the control group (p = 0.01). The causes of 
deaths in the study (AD) group were breast cancer related 
in 22 (7.9%) patients, related to a second primary in 2 
(0.7%) patients and related to other disease in 8 (2.9%) 
patients. Causes of deaths in the control group were breast 
cancer related in 28 (5.0%) patients, related to a second 
primary in 2 (0.4%) patients and related to other disease in 
6 (1.1%) patients. The 5-year OS rate was 92% (95% CI, 
87% to 94%) in the study group and 97% (95% CI, 95% 
to 98%) for the control group. The 10-year OS rate was 
86% (95% CI, 80% to 91%) in the study group and 90% 
(95% CI, 86% to 93%) for the control group (p = 0.0112). 
Figure 1, panel A and panel B, reports OS and DFS by 
study group. When looking at OS by surrogate intrinsic 
molecular subtypes, a statistically significant difference 
between study and control group was observed only 
in the ER positive/HER-2 negative subtype (p 0.0046, 
Figure 2); this difference remained statistically significant 
when the analysis was restricted to breast cancer mortality 
(9% breast cancer mortality at 10-yr in the study group 
vs 6% in the control group, p = 0.045). In terms of DFS, 
no significant differences were observed (p 0.22). The 
absence of differences in DFS remained in the surrogate 
intrinsic molecular subtypes analysis. Finally, we assessed 
a correlation between OS and specific type of ADs. We 
observed a definitely worse outcome for patients affected 
with vasculitis, although there were very few patients 
(Figure 3). 
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Table 1: Baseline demographic, clinical, and pathologic characteristics and local and systemic 
treatments of breast cancer patients with autoimmune disease (AD) and a matched cohort of breast 
cancer patients without AD




All patients 279 (100) 558 (100)
Type of AD
 endocrine 149 (53.4) – –
 rheumatic 66 (23.7)
 systemic 43 (15.4)
 vasculitis 7 (2.5)
 neurologic 14 (5.0)
Year of surgery matching variable
 < 1998 9 (3.2) 14 (2.5)
 1998–2001 48 (17.2) 97 (17.4)
 2002–2004 50 (17.9) 106 (19)
 2005–2007 97 (34.8) 199 (35.7)
 2008–2010 75 (26.9) 142 (25.4)
Age at surgery matching variable
 < 35 9 (3.2) 15 (2.7)
 35–50 109 (39.1) 220 (39.4)
 51–65 116 (41.6) 230 (41.2)
 > 65 45 (16.1) 93 (16.7)
Menopausal status matching variable
 Peri-Pre 125 (44.8) 250 (44.8)
 Post 154 (55.2) 308 (55.2)
Histology 0.58
 Ductal 225 (80.6) 437 (78.3)
 Lobular 25 (9) 63 (11.3)
 Mixed/Other 29 (10.4) 58 (10.4)
Tumor size (pT) 0.46
 pT1 179 (64.2) 374 (67.1)
 pT2 91 (32.6) 164 (29.4)
 pT3/pT4 9 (3.2) 20 (3.6)
No. of positive lymph nodes matching variable
 pNx 7 (2.5) 14 (2.5)
 None 154 (55.2) 308 (55.2)
 1–3 75 (26.9) 150 (26.9)
 4+ 43 (15.4) 86 (15.4)
Grade 0.16
 Unknown 12 (4.3) 15 (2.7)
 1–2 168 (60.2) 356 (63.8)
 3 99 (35.5) 187 (33.5)
Surrogate intrinsic subtype matching variable
 Luminal A 85 (30.5) 171 (30.6)
 Luminal B (Her2 negative) 104 (37.3) 212 (38)
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DISCUSSION
The aim of this study was to analyze the impact of 
a concurrent autoimmune disease on clinical outcomes 
of patients with early breast cancer. The clinical and 
pathological features of the two cohorts were well-
balanced. According to the results of our retrospective 
analysis ADs may impact on outcome of patients with 
early BC, thus suggesting that comorbidities may impact 
on therapeutic decision and treatment delivery, tolerability 
and compliance. Reluctance to prescribe systemic 
treatments was due to the complexity of evaluation for 
these patients and to the burden of symptoms related 
to concurrent ADs. Taking into account the data from 
the current study and given the climate of uncertainty 
regarding optimal treatment, we believe that physicians 
decided to individualize care on the basis of biologic 
characteristics, comorbidity, functional status, and patient 
preferences. We also evaluated whether ADs may affect 
BC outcome and response to treatment. In this series, 
the presence of ADs seems to negatively influence BC 
outcome, particularly OS. From survival analyses, we 
noticed that statistically significant better OS (p-value 
= 0.0112) was reported for BC patients with no ADs as 
compared to patients with BC and ADs, both at 5 (97% 
vs 92%) and 10 years (90% vs 86%), regardless of type 
of ADs.  Mortality rate was higher in patients with ADs 
(11.5% vs 6.4% in controls), and deaths were mainly 
due to BC in both cohorts. However, when OS data 
were analyzed according to tumor subtype, a statistical 
significant difference was observed only in the Luminal 
B/HER2-negative subtype. The potential explanation for 
this observation may be related to the poor compliance of 
patients to treatment with endocrine therapy. These agents 
may exacerbate arthralgia and other symptoms frequently 
associated to ADs. To determine appropriate intervention 
in this group of patients, it is therefore essential to perform 
a comprehensive baseline evaluation of musculoskeletal 
complaints. Our results are in conflict with those by 
Einefors et al, who showed improved BC outcome in 
patients with ADs [23]. Indeed, among the 1705 BC 
patients included in that analysis, those with coexisting 
AD (125 patients) had a not significant trend towards 
better OS, adjusted for age at diagnosis and TN stage 
(HR 0.91; CI 0.72–1.14). The benefit of the concurrent 
presence of AD or hypersensitivity disease (asthma or 
allergies) resulted to be higher for patients with ER-
negative BC, who achieve a significant  improvement of 
OS irrespective of menopausal status. This study analyzed 
BC outcome in the cohort through a multivariate analysis, 
whereas in our study the two cohorts were matched 
according to multiple parameters. ADs might influence BC 
outcome, like any comorbidity, for example by worsening 
the general health status of patients or by condition 
therapeutic options. Moreover, ADs could interfere with 
anti-cancer therapy, particularly with immunotherapeutics, 
such as trastuzumab, whose anti-cancer effect partly relies 
on antibody-dependent cell-mediated cytotoxicity. An 
 Luminal B (Her2 positive) 27 (9.7) 49 (8.8)
 Her2 positive 14 (5) 28 (5)
 Triple Negative 26 (9.3) 52 (9.3)
 Missing 23 (8.2) 46 (8.2)
Perivascular Invasion 0.71
 Absent 203 (72.8) 391 (70.1)
 Focal 46 (16.5) 103 (18.5)
 Diffuse 30 (10.8) 64 (11.5)
Surgery 0.82
 Conservative 213 (76.3) 430 (77.1)
 Mastectomy 66 (23.7) 128 (22.9)
Radiotherapy 0.24
 No 54 (19.4) 83 (14.9)
 Yes-External 143 (51.3) 309 (55.4)
 Yes-Intraoperative 82 (29.4) 166 (29.7)
Systemic adjuvant therapy 0.39
 Nil 21 (7.5) 27 (4.8)
 Endocrine therapy alone 147 (52.7) 310 (55.6)
 Chemotherapy alone 39 (14) 70 (12.5)
  Chemotherapy and 
endocrine therapy 72 (25.8) 151 (27.1)
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improved outcome was observed in BC patients with 
antithyroid peroxidase antibodies; moreover antithyroid 
peroxidase antibody positivity seems to be associated with 
a lower incidence of metastases in BC patients [24]. Other 
authors suggested that this could be due to the presence 
of a BC/thyroid shared antigens, probably antithyroid 
peroxidase antibody itself, that is weakly expressed in 
BC tissue and is responsible for the immunoreactivity 
showed in laboratory by antithyroid peroxidase antibodies 
positive patients serum against cancer tissue cells [25]. 
In another study was assessed the relationship between 
antiestrogen therapy in women with breast cancer and risk 
of autoimmune disease [26]. A national database was used 
to assess the incidence of systemic lupus erythematosus 
(SLE) and rheumatoid arthritis (RA) following treatment 
with selective estrogen receptor modulators (SERM) or 
aromatase inhibitors (AI) in women with breast cancer. 
The total number of patients in our study was 190,620. 
Authors observed highly significant, cumulative dose-
dependent increased OR of incidence of both SLE and 
RA following treatment with SERM (p < 0.0001) [26]. 
The odds of developing RA were also increased following 
AI therapy (p < 0.001), but there was a trend for reduced 
odds of SLE, though this trend did not attain statistical 
significance (p = 0.070 for 2-11 months of treatment and 
p = 0.254 for 12+ months of treatment). In this analysis 
Figure 1: Overall survival (Panel A) and Disease-free survival (Panel B), by study group.
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Figure 2: Overall survival by study group and surrogate intrinsic subtype.
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antiestrogen agents may have an important effect on 
risk of autoimmune disease [26]. Our study have several 
limitations. We used diagnosis of autoimmune diseases 
as a parameter to be correlated with the outcome of 
early breast cancer. The analysis included a variety 
of different diseases such ad autoimmune endocrine 
diseases, rheumatic diseases, systemic autoimmune 
diseases, and others. Given that all these diseases are 
characterized by different autoimmune mechanisms and 
come with different treatment approaches, we believe that 
this generalized approach has clear limitations. Another 
limitation is related to the different treatment regimens 
of the autoimmune diseases that should be taken into 
account when evaluating our data. For almost all patients 
we don’t have appropriate information on type treatment. 
Assessment of clinical outcome of the autoimmune 
disease activity would be more appropriate to elucidate 
potential causal interconnections. The results of our 
analysis confirm the relevance of ADs on the outcome 
of patients with early BC. In our study, autoimmune 
comorbidities in particular correlate significantly with a 
negative OS outcome in estrogen receptor positive disease. 
The presence of ADs should be considered when deciding 
on therapeutic strategies in patients with early BC. Further 
longitudinal studies are needed in order to confirm these 
findings, including also other comorbidity patterns, and to 
Figure 3: Overall survival (Panel A) and Disease-free survival (Panel B), by type of autoimmune disease.
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investigate the relationship between comorbidities, disease 
course and response to treatment. 
MATERIALS AND METHODS
We retrospectively retrieved from our Institutional 
prospective Breast Cancer Data Base - 279 consecutive 
patients with early breast cancer and concurrent 
autoimmune disease (AD), who underwent surgery at 
our Institution between 1994 and 2009. Patients with 
previous history of cancer, bilateral metastatic breast 
cancer were excluded, as well as patients who previously 
received neoadjuvant therapy.  We defined and categorized 
ADs as autoimmune endocrine diseases (i.e. thyroiditis, 
Basedow disease, type I diabetes), RA, systemic rheumatic 
diseases (i.e. RA), systemic autoimmune diseases (i.e. 
SEL, scleroderma disease, Sjogren syndrome, sclerotic 
cholangitis), neurologic autoimmune like diseases 
(i.e. miastenia gravis, sclerosis multiple, Guillain-
Barré syndrome) and vasculitis. A comparison group 
of 558 patients was obtained by randomly selecting, for 
each patient in the study group, two patients matched for 
year of diagnosis (within 2 years), age (within 5 years), 
menopausal status, number of positive lymph nodes and 
surrogate intrinsic subtype. Demographic data, clinical and 
biological features, treatment data for BC patients with 
ADs and for the matched group of BC patients without ADs 
were retrieved from the data base. Immunohistochemical 
staining for estrogen receptor (ER), PgR, HER2 protein 
and Ki-67 antigen was performed with consecutive tissue 
sections from the same tumor blocks. The following 
primary antibodies were used: the monoclonal antibody 
(mAb) against ER (clone 1D5, 1:100 dilution; Dako, 
Glostrup, Denmark), the mAb against PgR (clone 1A6, 
1:800 dilution; Dako), the MIB-1 mAb against Ki-67 
antigen (1:100 dilution; Dako) and the polyclonal antibody 
against HER2 protein (1:3,200 dilution; Dako). Only 
nuclear reactivity was taken into account for ER, PgR and 
Ki-67, irrespective of the staining intensity, whereas only 
intense and complete membrane staining in >10% of the 
tumor cells were considered HER2 overexpression (3+). 
In addition, fluorescence in situ hybridization assays were 
performed for the final determination of HER2 status for 
tumors with 2+ immunoreactivity. Median follow-up was 
7 years. OS, DFS and causes of death have been assessed 
and by surrogate intrinsic subtype. We also assessed any 
associations between type of ADs and overall survival.
Statistical analysis 
The chi-square test was used to assess differences 
between the study and the control group in the distribution 
of prognostic variables and treatment approaches. The 
main endpoints were overall survival (OS) and disease-
free survival (DFS). OS was defined as the length of 
time from the date of surgery to death from any cause. 
DFS was defined as the length of time from the date of 
surgery to events such as relapse (including ipsilateral 
breast recurrence), appearance of a second primary cancer 
(including contralateral breast cancer), or death, whichever 
occurred first. For survivors, OS and DFS were censored 
at the last follow-up visit. The OS and DFS distributions 
were estimated by using the Kaplan-Meier method, and 
the log-rank test was used to test differences in survival 
distributions between study and control group.
CONFLICTS OF INTEREST
Authors declare no conflicts of interest.
GRANT SUPPORT
This study received no grant support.
REFERENCES
1. Li YR, Zhao SD, Li J, Bradfield JP, Mohebnasab M, Steel L, 
Kobie J, Abrams DJ, Mentch FD, Glessner JT, Guo Y, 
Wei Z, Connolly JJ, et al. Genetic sharing and heritability of 
paediatric age of onset autoimmune diseases. Nat Commun. 
2015; 6:8442.
2. Holmqvist AS, Olsen JH, Mellemkjaer L, Garwicz S, 
Hjorth L, Moell C, Månsson B, Tryggvadottir L, Hasle H, 
Winther JF. Autoimmune diseases in Adult Life after 
Childhood Cancer in Scandinavia (ALiCCS). Ann Rheum 
Dis. 2015.
3. Weiner HL. Induction and mechanism of action of 
transforming growth factor-beta-secreting Th3 regulatory 
cells. Immunol Rev. 2001; 182:207–14.
4. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, 
Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, 
Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, et al. Specific 
recruitment of regulatory T cells in ovarian carcinoma 
fosters immune privilege and predicts reduced survival. Nat 
Med. 2004; 10:942–9.
5. Horwitz DA, Zheng SG, Gray JD, Wang JH, Ohtsuka K, 
Yamagiwa S. Regulatory T cells generated ex vivo as an 
approach for the therapy of autoimmune disease. Semin 
Immunol. 2004; 16:135–43.
6. Hori S, Takahashi T, Sakaguchi S. Control of autoimmunity 
by naturally arising regulatory CD4+ T cells. Adv Immunol. 
2003; 81:331–71.
7. Wan YY, Flavell RA. Regulatory T cells, transforming 
growth factor-beta, and immune suppression. Proc Am 
Thorac Soc. 2007; 4:271–6.
8. Afzali B, Lombardi G, Lechler RI, Lord GM. The role of 
T helper 17 (Th17) and regulatory T cells (Treg) in human 
organ transplantation and autoimmune disease. Clin Exp 
Immunol. 2007; 148:32–46.
9. Kryczek I, Liu R, Wang G, Wu K, Shu X, Szeliga W, 
Vatan L, Finlayson E, Huang E, Simeone D, Redman B, 
Oncotarget51192www.impactjournals.com/oncotarget
Welling TH, Chang A, et al. FOXP3 defines regulatory T 
cells in human tumor and autoimmune disease. Cancer Res. 
2009; 69:3995–4000.
10. Linden A, Dahlen B. Interleukin-17 cytokine signalling in 
patients with asthma. Eur Respir J. 2014; 44:1319–31.
11. Kolls JK, Linden A. Interleukin-17 family members and 
inflammation. Immunity. 2004; 21:467–76.
12. Martin-Orozco N, Dong C. The IL-17/IL-23 axis of 
inflammation in cancer: friend or foe? Curr Opin Investig 
Drugs. 2009; 10:543–9.
13. Ciric B, El-behi M, Cabrera R, Zhang GX, Rostami A. 
IL-23 drives pathogenic IL-17-producing CD8+ T cells. 
J Immunol. 2009; 182:5296–305.
14. Khosravi-Maharlooei M, Pakyari M, R BJ, Salimi-Elizei S, 
Lai JC, Poormasjedi-Meibod M, Kilani RT, Dutz J, 
Ghahary A. Tolerogenic Effect of Mouse Fibroblasts on 
Dendritic Cells. Immunology. 2016.
15. Kiss E, Kovacs L, Szodoray P. Malignancies in 
systemic lupus erythematosus. Autoimmun Rev. 2010; 
9:195–9.
16. Zampieri S, Valente M, Adami N, Biral D, Ghirardello A, 
Rampudda ME, Vecchiato M, Sarzo G, Corbianco S, 
Kern H, Carraro U, Bassetto F, Merigliano S, et al. 
Polymyositis, dermatomyositis and malignancy: a further 
intriguing link. Autoimmun Rev. 2010; 9:449–53.
17. Franks AL, Slansky JE. Multiple associations between 
a broad spectrum of autoimmune diseases, chronic 
inflammatory diseases and cancer. Anticancer research. 
2012; 32:1119–36.
18. Prinzi N, Sorrenti S, Baldini E, De Vito C, Tuccilli C, 
Catania A, Coccaro C, Bianchini M, Nesca A, Grani G, 
Mocini R, De Antoni E, D'Armiento M, et al. Association of 
thyroid diseases with primary extra-thyroidal malignancies 
in women: results of a cross-sectional study of 6,386 
patients. PloS one. 2015; 10:e0122958.
19. Chen YK, Lin CL, Chang YJ, Cheng FT, Peng CL, 
Sung FC, Cheng YH, Kao CH. Cancer risk in patients with 
Graves’ disease: a nationwide cohort study. Thyroid. 2013; 
23:879–84.
20. Hardefeldt PJ, Eslick GD, Edirimanne S. Benign thyroid 
disease is associated with breast cancer: a meta-analysis. 
Breast Cancer Res Treat. 2012; 133:1169–77.
21. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, 
Smith DC, McDermott DF, Powderly JD, Carvajal RD, 
Sosman JA, Atkins MB, Leming PD, Spigel DR, 
Antonia SJ, et al. Safety, activity, and immune correlates 
of anti-PD-1 antibody in cancer. T N Engl J Med. 2012; 
366:2443–54.
22. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, 
Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, 
Pitot HC, Hamid O, Bhatia S, et al. Safety and activity of 
anti-PD-L1 antibody in patients with advanced cancer. N 
Engl J Med. 2012; 366:2455–65.
23. Einefors R, Kogler U, Ellberg C, Olsson H. Autoimmune 
diseases and hypersensitivities improve the prognosis in 
ER-negative breast cancer. SpringerPlus. 2013; 2:357.
24. Kemal Y, Demirag G, Ekiz K, Yucel I. Antithyroid 
peroxidase antibody positivity is associated with lower 
incidence of metastasis in breast cancer. Mol Clin Oncol. 
2015; 3:629–32.
25. Muller I, Giani C, Zhang L, Grennan-Jones FA, Fiore E, 
Belardi V, Rosellini V, Funel N, Campani D, Giustarini E, 
Lewis MD, Bakhsh AD, Roncella M, et al. Does thyroid 
peroxidase provide an antigenic link between thyroid 
autoimmunity and breast cancer? Int J Cancer. 2014; 
134:1706–14.
26. Chen JY, Ballou SP. The effect of antiestrogen agents on 
risk of autoimmune disorders in patients with breast cancer. 
J Rheumatol. 2015; 42:55–9.
